BioPharmX (NYSEMKT:BPMX) Rating Maintained
In a research note sent to clients and investors on 13 September, BioPharmX (NYSEMKT:BPMX) stock had its “Buy” Rating reconfirmed by equity research analysts at Maxim Group. They currently have a $1.5 target on firm. Maxim Group’s target means a potential upside of 341.18 % from the company’s last stock close.
NYSEMKT:BPMX is now trading -11.76% lower at $0.30 as of 8:07 AM New York time. BioPharmX’s stock is 0% in the last 200 days. It has underperformed the S&P500, which has risen 6.00% in the same time.
BioPharmX (NYSEMKT:BPMX) Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
BioPharmX (NYSEMKT:BPMX) traded down -11.76% on 13 September, hitting $0.3. A total of 1.39M shares of the company’s stock traded hands. This is up from average of 744,452 shares. BioPharmX has a 52 week low of $0.19 and a 52 week high of $0.9. The company has a market cap of $23.89M and a P/E ratio of 0.
Get the latest BioPharmX (NYSEMKT:BPMX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.